ALTAMIRA THERAPEUTICS LTD (CYTO) Stock Price, Quote, News and Overview
NASDAQ:CYTO - Nasdaq - BMG0360L1349 - Common Stock - Currency: USD
CYTO Quote, Performance and Key Statistics
0.3
-0.11 (-25.94%)
The current stock price of CYTO is 0.3 USD. In the past month the price decreased by -31.8%. In the past year, price decreased by -89.47%.
CYTO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About CYTO
Company Profile
Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. The firm has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.
Company Info
ALTAMIRA THERAPEUTICS LTD
Clarendon House, 2 Church Street
Hamilton ZUG BM
CEO: Thomas Meyer
Employees: 10
Company Website: https://aurismedical.com/
Investor Relations: https://ir.aurismedical.com/
Phone: 410417297194
ALTAMIRA THERAPEUTICS LTD / CYTO FAQ
What is the stock price of ALTAMIRA THERAPEUTICS LTD today?
The current stock price of CYTO is 0.3 USD. The price decreased by -25.94% in the last trading session.
What is the ticker symbol for ALTAMIRA THERAPEUTICS LTD stock?
The exchange symbol of ALTAMIRA THERAPEUTICS LTD is CYTO and it is listed on the Nasdaq exchange.
On which exchange is CYTO stock listed?
CYTO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ALTAMIRA THERAPEUTICS LTD stock?
7 analysts have analysed CYTO and the average price target is 5.41 USD. This implies a price increase of 1702% is expected in the next year compared to the current price of 0.3. Check the ALTAMIRA THERAPEUTICS LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALTAMIRA THERAPEUTICS LTD worth?
ALTAMIRA THERAPEUTICS LTD (CYTO) has a market capitalization of 1.13M USD. This makes CYTO a Nano Cap stock.
How many employees does ALTAMIRA THERAPEUTICS LTD have?
ALTAMIRA THERAPEUTICS LTD (CYTO) currently has 10 employees.
What are the support and resistance levels for ALTAMIRA THERAPEUTICS LTD (CYTO) stock?
ALTAMIRA THERAPEUTICS LTD (CYTO) has a resistance level at 0.42. Check the full technical report for a detailed analysis of CYTO support and resistance levels.
Is ALTAMIRA THERAPEUTICS LTD (CYTO) expected to grow?
The Revenue of ALTAMIRA THERAPEUTICS LTD (CYTO) is expected to decline by -100% in the next year. Check the estimates tab for more information on the CYTO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ALTAMIRA THERAPEUTICS LTD (CYTO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CYTO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CYTO, evaluating the profitability, health, valuation and growth aspects
- ALTAMIRA THERAPEUTICS LTD (CYTO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALTAMIRA THERAPEUTICS LTD (CYTO) Sales and EPS estimates to see what analysts future expectations are.
- ALTAMIRA THERAPEUTICS LTD (CYTO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALTAMIRA THERAPEUTICS LTD (CYTO) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALTAMIRA THERAPEUTICS LTD (CYTO) Stock Chart to make your own analysis
- ALTAMIRA THERAPEUTICS LTD (CYTO) Latest news and press-releases to stay up to date.
Does ALTAMIRA THERAPEUTICS LTD (CYTO) stock pay dividends?
CYTO does not pay a dividend.
What is the Price/Earnings (PE) ratio of ALTAMIRA THERAPEUTICS LTD (CYTO)?
The PE ratio for ALTAMIRA THERAPEUTICS LTD (CYTO) is 0.36. This is based on the reported non-GAAP earnings per share of 0.83 and the current share price of 0.3 USD. Check the full fundamental report for a full analysis of the valuation metrics for CYTO.
CYTO Technical Analysis
CYTO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CYTO. CYTO may be in some trouble as it scores bad on both profitability and health.
CYTO Financial Highlights
Over the last trailing twelve months CYTO reported a non-GAAP Earnings per Share(EPS) of 0.83. The EPS increased by 101.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.09% | ||
| ROE | -0.11% | ||
| Debt/Equity | 0.05 |
CYTO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CYTO. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -88.67% and a revenue growth -100% for CYTO